Character Biosciences is a precision medicine company pioneering targeted therapies for polygenic diseases, with an initial focus on ophthalmology. Our patient data platform integrates genomics with deep, longitudinal clinical and imaging data, enabling us to uncover genetic drivers of disease progression, advance novel therapeutics, and define patient stratification strategies that improve clinical success. Our interdisciplinary team, comprising experts in clinical science, data science, statistical genetics, computer vision, and drug discovery, utilizes this platform to determine genetic drivers of disease progression, advance novel therapeutics and define genetics-based patient stratification. Powered by our data platform, Character Bio is currently advancing two programs in Dry Age-related Macular Degeneration (AMD) with additional programs for other disease areas (e.g. Glaucoma) in earlier stages of discovery research. Founded in 2018, Character has raised capital from leading investors at the intersection of healthcare and technology, including an oversubscribed $110+ million Series B in 2025 co-led by aMoon and Luma Group, with participation from Bausch + Lomb, Sanofi Ventures, Innovation Endeavors, Catalio Capital Management, S32, KdT Ventures, and Jefferson Life Sciences. We also maintain a multi-target drug discovery collaboration with Bausch + Lomb to develop innovative precision medicines for AMD.